Published in Adv Immunol on January 01, 2008
Autoimmune T cell responses in the central nervous system. Nat Rev Immunol (2009) 4.73
B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci Transl Med (2014) 1.49
The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol (2014) 1.11
Immunity and inflammation in neurodegenerative diseases. Am J Neurodegener Dis (2013) 1.08
Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations. J Neurol (2008) 1.08
A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neuroimmunol (2010) 0.99
Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord (2010) 0.98
Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis. J Neuroimmunol (2009) 0.96
Protein array-based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis. Neurology (2013) 0.91
The skin, a novel niche for recirculating B cells. J Immunol (2012) 0.89
Ophthalmopathology in rats with MBP-induced experimental autoimmune encephalomyelitis. Graefes Arch Clin Exp Ophthalmol (2011) 0.87
Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges. MAbs (2010) 0.86
Peptide reactivity between multiple sclerosis (MS) CSF IgG and recombinant antibodies generated from clonally expanded plasma cells in MS CSF. J Neuroimmunol (2010) 0.86
The double-edged sword of autoimmunity: lessons from multiple sclerosis. Toxins (Basel) (2010) 0.83
The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases. Neurol Sci (2011) 0.81
CD98 is a potential target for ablating B cell clonal expansion and autoantibody in multiple sclerosis. J Neuroimmunol (2014) 0.78
Coherent somatic mutation in autoimmune disease. PLoS One (2014) 0.78
Glatiramer acetate for treatment of MS: regulatory B cells join the cast of players. Exp Neurol (2010) 0.77
Investigating the Antigen Specificity of Multiple Sclerosis Central Nervous System-Derived Immunoglobulins. Front Immunol (2015) 0.77
Tolerogenic vaccines for Multiple sclerosis. Hum Vaccin Immunother (2013) 0.77
Development of anti-CD20 therapy for multiple sclerosis. Exp Cell Res (2011) 0.77
DNA Methylation: a New Player in Multiple Sclerosis. Mol Neurobiol (2016) 0.76
Identifying patient subtypes in multiple sclerosis and tailoring immunotherapy: challenges for the future. Ther Adv Neurol Disord (2009) 0.75
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med (2007) 17.06
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med (2004) 14.53
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
Multiple sclerosis. N Engl J Med (2000) 12.69
Axonal transection in the lesions of multiple sclerosis. N Engl J Med (1998) 12.21
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
Germinal centers. Annu Rev Immunol (1994) 10.85
Antigen-specific interaction between T and B cells. Nature (1985) 10.64
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39
Systemic lupus erythematosus. N Engl J Med (2008) 10.22
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol (2000) 9.73
Immunology of multiple sclerosis. Annu Rev Immunol (2005) 9.08
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
B cells regulate autoimmunity by provision of IL-10. Nat Immunol (2002) 7.30
Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med (2003) 6.73
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 6.47
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol (2008) 6.09
Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev (2006) 6.08
Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci (1997) 5.68
Transvascular delivery of small interfering RNA to the central nervous system. Nature (2007) 5.21
Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med (2003) 4.86
Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain (2007) 4.82
Th17: the third member of the effector T cell trilogy. Curr Opin Immunol (2007) 4.78
Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol (2000) 4.73
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology (1999) 4.53
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol (2006) 4.46
Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology (2007) 4.23
Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes (1996) 4.20
Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity (2004) 4.00
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain (2007) 3.88
Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology (2007) 3.83
Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol (2004) 3.74
A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med (1999) 3.74
Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med (1999) 3.66
Active induction of experimental allergic encephalomyelitis. Nat Protoc (2006) 3.64
Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature (2005) 3.62
The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron (2006) 3.55
B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J Exp Med (1996) 3.35
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26
Antigen processing and class II MHC peptide-loading compartments in human B-lymphoblastoid cells. Nature (1994) 3.23
B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol (2006) 3.20
A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet (1996) 3.00
Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes (1999) 3.00
An open label study of the effects of rituximab in neuromyelitis optica. Neurology (2005) 2.99
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet (1996) 2.98
Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain (2000) 2.96
Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol (1988) 2.93
Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology (2002) 2.90
Acute disseminated encephalomyelitis. Neurology (2007) 2.84
Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest (2006) 2.75
Plasma-cell homing. Nat Rev Immunol (2003) 2.74
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol (1999) 2.69
Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol (2007) 2.68
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med (2007) 2.64
The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol (1995) 2.57
The prevalence of multiple sclerosis in the world: an update. Neurol Sci (2001) 2.57
Signal transduction by the B cell antigen receptor and its coreceptors. Annu Rev Immunol (1994) 2.52
Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest (2004) 2.34
Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest (2006) 2.32
Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology (2007) 2.32
B lymphocytes induce the formation of follicular dendritic cell clusters in a lymphotoxin alpha-dependent fashion. J Exp Med (1998) 2.32
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum (2007) 2.31
Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med (2005) 2.31
Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med (2001) 2.27
B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol (1999) 2.13
Basic principles of immunological surveillance of the normal central nervous system. Glia (2001) 2.13
Mature follicular dendritic cell networks depend on expression of lymphotoxin beta receptor by radioresistant stromal cells and of lymphotoxin beta and tumor necrosis factor by B cells. J Exp Med (1999) 2.11
Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol (2003) 2.10
A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody. J Neuroimmunol (1984) 2.09
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol (2006) 2.06
B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol (1999) 2.06
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology (2004) 2.04
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol (2005) 2.02
Frontline: Epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination. Eur J Immunol (2004) 2.01
Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest (1991) 2.01
Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest (2005) 1.95
A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol (1998) 1.95
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med (2005) 1.92
Multiple sclerosis. Immunol Rev (2005) 1.92
Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol (2004) 1.89
Comparison of immunoglobulin G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven response. Neurology (2000) 1.84
Isolated lymphoid follicle formation is inducible and dependent upon lymphotoxin-sufficient B lymphocytes, lymphotoxin beta receptor, and TNF receptor I function. J Immunol (2003) 1.84
Primary progressive multiple sclerosis. Brain (1997) 1.80
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.79
B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization. J Immunol (1998) 1.79
Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med (2007) 1.77
Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes (2004) 1.76
The sequential role of lymphotoxin and B cells in the development of splenic follicles. J Exp Med (1998) 1.72
Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol (2004) 1.71
Production of cytokines by human B cells in health and disease. Immunol Today (1997) 1.66
Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med (2004) 1.66
Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol (2000) 1.64
Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med (2007) 7.73
Regulation of T cell receptor activation by dynamic membrane binding of the CD3epsilon cytoplasmic tyrosine-based motif. Cell (2008) 4.00
Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest (2003) 3.40
Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nat Immunol (2005) 3.05
The organizing principle in the formation of the T cell receptor-CD3 complex. Cell (2002) 2.74
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med (2007) 2.64
Myelin proteolipid protein-specific CD4+CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2004) 2.34
Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. Immunity (2007) 2.23
The structure of the zetazeta transmembrane dimer reveals features essential for its assembly with the T cell receptor. Cell (2006) 1.95
The assembly of diverse immune receptors is focused on a polar membrane-embedded interaction site. PLoS Biol (2006) 1.83
Detection of autoreactive myelin proteolipid protein 139-151-specific T cells by using MHC II (IAs) tetramers. J Immunol (2003) 1.71
The T cell receptor: critical role of the membrane environment in receptor assembly and function. Annu Rev Immunol (2005) 1.64
Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID). J Clin Invest (2007) 1.58
Common themes in the assembly and architecture of activating immune receptors. Nat Rev Immunol (2007) 1.54
The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci U S A (2005) 1.54
Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2. Immunity (2012) 1.50
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol (2009) 1.50
The structural basis for intramembrane assembly of an activating immunoreceptor complex. Nat Immunol (2010) 1.44
Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol (2005) 1.43
Self-reactive human CD4 T cell clones form unusual immunological synapses. J Exp Med (2012) 1.38
HLA-DM captures partially empty HLA-DR molecules for catalyzed removal of peptide. Nat Immunol (2010) 1.38
Convergence on a distinctive assembly mechanism by unrelated families of activating immune receptors. Immunity (2005) 1.36
A highly tilted binding mode by a self-reactive T cell receptor results in altered engagement of peptide and MHC. J Exp Med (2011) 1.34
Molecular mechanisms for the assembly of the T cell receptor-CD3 complex. Mol Immunol (2004) 1.30
Induction of antigen-specific regulatory T cells in wild-type mice: visualization and targets of suppression. Proc Natl Acad Sci U S A (2008) 1.30
Stoichiometry of the T-cell receptor-CD3 complex and key intermediates assembled in the endoplasmic reticulum. EMBO J (2004) 1.28
Cutting edge: CD4+CD25+ regulatory T cells contribute to gender differences in susceptibility to experimental autoimmune encephalomyelitis. J Immunol (2005) 1.28
Ex vivo analysis of thymic CD4 T cells in nonobese diabetic mice with tetramers generated from I-A(g7)/class II-associated invariant chain peptide precursors. J Immunol (2003) 1.22
Crystal structure of the HLA-DM-HLA-DR1 complex defines mechanisms for rapid peptide selection. Cell (2012) 1.21
Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol (2003) 1.16
Empty class II major histocompatibility complex created by peptide photolysis establishes the role of DM in peptide association. J Biol Chem (2007) 1.16
Structural factors contributing to DM susceptibility of MHC class II/peptide complexes. J Immunol (2002) 1.14
Alternative RISC assembly: binding and repression of microRNA-mRNA duplexes by human Ago proteins. RNA (2012) 1.13
Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence. J Clin Invest (2010) 1.13
MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One (2011) 1.12
Small molecules that enhance the catalytic efficiency of HLA-DM. J Immunol (2006) 1.10
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
Suppression of autoimmune disease after vaccination with autoreactive T cells that express Qa-1 peptide complexes. J Clin Invest (2004) 1.08
Expansion and contraction of HIV-specific CD4 T cells with short bursts of viremia, but physical loss of the majority of these cells with sustained viral replication. J Immunol (2005) 1.08
Suppression of autoimmune diabetes by soluble galectin-1. J Immunol (2009) 1.06
A spontaneous model for autoimmune myocarditis using the human MHC molecule HLA-DQ8. J Immunol (2004) 1.05
Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals. J Clin Invest (2014) 1.04
Structural basis of T-cell specificity and activation by the bacterial superantigen TSST-1. EMBO J (2007) 1.03
Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. J Virol (2008) 1.03
Local changes in lipid environment of TCR microclusters regulate membrane binding by the CD3ε cytoplasmic domain. J Exp Med (2012) 0.98
A membrane-proximal tetracysteine motif contributes to assembly of CD3deltaepsilon and CD3gammaepsilon dimers with the T cell receptor. J Biol Chem (2006) 0.97
Unusual features of self-peptide/MHC binding by autoimmune T cell receptors. Immunity (2005) 0.97
The mechanism of HLA-DM induced peptide exchange in the MHC class II antigen presentation pathway. Curr Opin Immunol (2011) 0.95
The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood (2003) 0.94
In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange. J Immunol (2009) 0.93
Prevention of type 1 diabetes by gene therapy. J Clin Invest (2004) 0.91
Response multilayered control of T cell receptor phosphorylation. Cell (2010) 0.89
Mechanisms of peptide repertoire selection by HLA-DM. Trends Immunol (2013) 0.89
Functional single-cell analysis of T-cell activation by supported lipid bilayer-tethered ligands on arrays of nanowells. Lab Chip (2012) 0.89
Identification of HIV-1-specific regulatory T-cells using HLA class II tetramers. AIDS (2012) 0.88
Measuring T cell immunity to influenza vaccination in children after haemopoietic stem cell transplantation. Br J Haematol (2004) 0.87
Cross-reactive TCR responses to self antigens presented by different MHC class II molecules. J Immunol (2004) 0.85
Crossreactivity of a human autoimmune TCR is dominated by a single TCR loop. Nat Commun (2013) 0.83
Expression of the B7.1 costimulatory molecule on pancreatic beta cells abrogates the requirement for CD4 T cells in the development of type 1 diabetes. J Immunol (2004) 0.83
Self-peptides that bind with low affinity to the diabetes-associated I-A(g7) molecule readily induce T cell tolerance in non-obese diabetic mice. Eur J Immunol (2004) 0.81
Immunomodulation for glioblastoma. Curr Opin Neurol (2017) 0.81
Cell surface display of functional human MHC class II proteins: yeast display versus insect cell display. Protein Eng Des Sel (2011) 0.80
Infectious triggers for inflammatory neurological diseases. Nat Med (2002) 0.79
Ex vivo analysis of human T lymphotropic virus type 1-specific CD4+ cells by use of a major histocompatibility complex class II tetramer composed of a neurological disease-susceptibility allele and its immunodominant peptide. J Infect Dis (2007) 0.78
Positively selecting peptides: their job does not end in the thymus. Nat Immunol (2009) 0.76
Cracking the code of human T-cell immunity. Nat Biotechnol (2013) 0.75
Erratum: The microRNA miR-31 inhibits CD8(+) T cell function in chronic viral infection. Nat Immunol (2017) 0.75
Autoimmune diseases have been the focus of intense research efforts. Curr Opin Immunol (2011) 0.75